Q-omics provides the consensus-scored ARL14EP profile across patient tissues and cancer cell-line models. ARL14EP expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, ARL14EP is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, ARL14EP protein abundance shows 20,671 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BRCA, THCA, and GBM as cancer lineages where ARL14EP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARL14EP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARL14EP survival associations across molecular data types. ARL14EP RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARL14EP RNA expression–survival associations across cancer types. High ARL14EP expression shows unfavorable associations in LIHC and KIRP, but favorable associations in BRCA, KIRC, READ and LUAD. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for ARL14EP RNA expression.
This table summarizes ARL14EP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ARL14EP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARL14EP shows lower tumor expression in THCA, BLCA and KIRP and higher tumor expression in LIHC, CHOL and COAD. The THCA box plot shows higher ARL14EP RNA expression in normal versus tumor tissue (log2 FC = −0.894, t-test p < 0.001).
This table shows molecular features associated with ARL14EP in patient tissues and cancer cell lines. In patient samples, ARL14EP shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ARL14EP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and UPPER_AERODIGESTIVE_TRACT.
